Particle Works, a leading provider of game-changing microfluidic nanoparticle synthesis platforms, is collaborating with NanoVation Therapeutics UK to reduce the time and costs associated with the screening of new lipid nanoparticle (LNP) formulations for use in drug delivery applications. Through this partnership, Oxfordshire-based NanoVation will benefit from Particle Works' Automated Library Synthesis (ALiS) System, which accelerates LNP formulation development while increasing throughput and precision.
ALiS is a high-throughput formulation screening platform that automates the preparation of LNP formulation. Image Credit: Particle Works
ALiS is a state-of-the-art, high-throughput formulation screening platform that automates the preparation of nanoparticle formulations for various applications, including drug discovery, gene therapy and vaccine development. Launched in October 2022, the system has already proven to be a valuable asset for scientists seeking an automated, cost-effective and efficient way to screen LNP formulations and mRNA candidates in early-stage development. ALiS is the latest in a range of automated microfluidic systems designed for use at specific stages of the nanoparticle formulation development process. At each stage, ALiS employs the same reusable glass microfluidic chips and pumping technology, ensuring the precise production of consistent size and structure particles throughout the development pipeline.
“We are delighted to partner with NanoVation and support the company’s efforts to develop new LNP formulations,” explained Lee Jeffries, Managing Director of Particle Works. “ALiS is designed for the automated and high-throughput screening of nanoparticle formulations, and we believe it can play a critical role in helping NanoVation to accelerate the development of its future projects. Our team at Particle Works is committed to providing innovative solutions that can drive breakthroughs in research and development, and we believe this collaboration is a great step in that direction. We look forward to holding future workshops with the NanoVation team."
"We are very excited to partner with Particle Works and to use its ALiS platform in our LNP research,” said Arpan Desai, Managing Director of NanoVation Therapeutics UK. “There is nothing on the market quite like it, and we believe it will be a game changer for the high-throughput screening of our formulations. ALiS' ability to automate the preparation of nanoparticle formulations is unique, and we are excited to see the impact it will have on our work."